Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

FDA Approvals, News & Updates

Tibsovo FDA Approved, with Azacitidine, for Newly Diagnosed Patients with Acute Myeloid Leukemia and IDH1 Mutation

Yescarta First CAR T-Cell Therapy FDA Approved for Patients with Large B-Cell Lymphoma

Kymriah, a CAR T-Cell Immunotherapy, FDA Approved for Patients with Follicular Lymphoma

Enhertu Received Regular FDA Approval for Unresectable or Metastatic Breast Cancer

Opdualag a Novel Immunotherapy Combination FDA Approved for Patients with Advanced Melanoma

Pluvicto FDA Approved for Men with PSMA-Positive Metastatic Prostate Cancer

Carvykti Second CAR T-Cell Therapy FDA Approved for Patients with Multiple Myeloma

Keytruda Monotherapy FDA Approved for Patients with Endometrial Carcinoma with a Biomarker

Opdivo plus Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage Non–Small-Cell Lung Cancer

Kimmtrak First Drug FDA Approved for Metastatic Uveal Melanoma
In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn), a novel type of immunotherapy, for the treatment of adults with advanced or spreading uveal melanoma, a rare and aggressive type of melanoma that affects the eye. Kimmtrak is the first drug approved for this type of melanoma. Read More ›

Page 3 of 16